What is Exicure?
Exicure, Inc. is a development-stage biotechnology company headquartered in Chicago, IL. The company's core innovation lies in its proprietary Spherical Nucleic Acid (SNA) technology, which it believes offers distinct chemical and biological advantages over other nucleic acid therapeutics. Exicure aims to leverage this technology to create therapeutic solutions for a range of neurological and other genetic disorders, potentially addressing unmet medical needs in areas not typically targeted by existing therapies. The company's focus on SNA technology positions it at the forefront of nucleic acid-based drug development.
How much funding has Exicure raised?
Exicure has raised a total of $116.9M across 11 funding rounds:
Series B
$5.4M
Series C
$13.6M
Other Financing Round
$14.8M
Share Placement
$20M
Share Placement
$11.2M
Debt
$350K
Debt
$25M
Private Equity
$5.4M
Private Equity
$10M
Share Placement
$8.7M
Series B (2012): $5.4M led by David R. Walt, Patrick Ryan, Eric Schmidt, Abbott Biotech Ventures, and Craig Mundie
Series C (2014): $13.6M supported by Bill Gates, Craig Mundie, Patrick Ryan, and Boon Hwee Koh
Other Financing Round (2015): $14.8M featuring Liz Lefkofsky and Tempus
Share Placement (2017): $20M backed by Patrick G. Ryan, AbbVie, David R. Walt, Mark Tompkins, Katalyst Securities, Craig Mundie, and Tempus
Share Placement (2017): $11.2M with participation from Luye Pharma Group
Debt (2020): $350K led by PPP
Debt (2020): $25M, investors not publicly disclosed
Private Equity (2022): $5.4M featuring CBI USA
Private Equity (2024): $10M backed by Hitron Systems
Share Placement (2024): $8.7M, investors not publicly disclosed
Key Investors in Exicure
Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.
Bill Gates
Gates Notes is Bill Gates' personal blog, where he shares about the people he meets, the books he's reading, and what he's learning. This indicates an interest in innovative ventures and potentially impactful technologies.
Abbott Biotech Ventures
AbbVie is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions. Their investment suggests a strategic interest in novel therapeutic approaches within the biotechnology sector.
What's next for Exicure?
With a substantial enterprise-level funding history and a recent strategic investment, Exicure appears to be in a scaling phase, poised to advance its pipeline of SNA-based therapeutics. The company's commitment to innovation in neurology and genetic disorders, coupled with its proprietary technology, suggests a strategic focus on high-impact therapeutic areas. Future developments will likely center on clinical trial progress, potential partnerships, and the expansion of its research and development capabilities to translate its promising technology into viable treatments for patients with complex conditions.
See full Exicure company page
